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The increase of herbal medicine use led many scientists to contribute to the research in this
field. Also a few pharmacologists, after an initial phase of correct criticisms, today recognize
the possibility of investigating the scientific value of medicinal products composed essentially of
vegetable extracts. However, it is logical to pose the questions: (i) is there a role for the
pharmacologist in herbal medicine (or phytotherapy)? (ii) can we do without pharmacologists’?
First, two worlds—drug researchers (pharmacologists) and herbal medicines—yesterday
appearing in opposition, are today closer and it is not unusual to read scientific works
describing herbal extracts in journals traditionally dedicated to the study of synthetic drugs.
Second, clinical application of herbal medicines is evaluable through the methods of modern
clinical pharmacology. Efficacy and safety of medicinal plants represent naturally the object of
interest for the pharmacologist and it is surely this aspect which gives the most important
information on herbal medicine use. Many plants have been studied and results published
showing, one time good or another poor, efficacy. Safety aspects of some of the most frequently
used plants are now well known. For example, today we learn to use hypericum and we do not
give it to patients taking other drugs because the interactions of hypericum with them.
Contraindications of other plants, often represented by interactions with drugs, are finally
known (Ginkgo biloba and drugs acting on blood coagulation). In conclusion, antagonistic
behavior of pharmacologists versus herbal medicines is not useful. On the contrary, modern
phytotherapy needs the contribution of researchers usually trained to evaluate efficacy and
safety of medicinals.
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Herbal Medicine and Pharmacologists:
Debating is Possible
In the last decade there has been a rapidly growing use of
herbal medicines. This phenomenon which captured the
attention of many scientists led them to play a role in this
research. Modern pharmacology is for the most part
directly derived from plants, but it is also well known that
the use of active principles (drugs) contained in them has
been considered an important progress in the care of
diseases. However, a growing group of pharmacologists
today, after an initial phase of pertinent criticisms of some
aspects of herbal medicine still extremely based on
experience, recognize the possibility of analyzing the
scientific basis of biological effects produced by medicinal
products composed essentially of vegetable extracts (1).
The times have changed and we think that to debate on
herbal medicines without a strong influence of cultural
barriers with respect to the recent past is possible. It is
reasonable to pose some questions: (i) is there a role for
the pharmacologist in herbal medicine (or phytotherapy)?
can herbal medicine context do without pharmacologist?
Two considerations are interesting. First, two worlds—
drug researchers (pharmacologists) and herbal
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properly cited.medicines—yesterday appearing in opposition, are today
closer. During the last decade reading scientific works
on pharmacological effects and mechanisms of action of
herbal extracts described by pharmacologists (including
the authors of this article) and published in journals
traditionally dedicated to synthetic drugs became more
frequent (2,3).
Second, also clinical application of herbal medicines is
evaluable through the methods of modern clinical
pharmacology. It is difficult to challenge the assumption
that clinical trial methodology is not applicable to
vegetable products. Actually the production of extracts,
tinctures and other herbal preparations has reached
acceptable levels allowing them to be standardized and
giving to these medicinals characteristics adequate to the
application of rules regulating clinical research of
synthetic drugs (4).
Furthermore, efficacy and safety of products based on
medicinal plants represent a natural object of interest for
the pharmacologist. The evaluation of clinical efficacy
and safety of herbal medicines with the goal to know if
they are efficient to treat diseases and if their use is free
of damage to the health of consumers is surely the most
important aspect either for medical community or public
opinion (5). In this way, different plants have been
studied and results published showing, one time good or
another poor, efficacy. Thanks to this work, actually in
progress, safety aspects of certain most frequently used
plants are now well known (6).
Safety from Long Standing Use
Can a medicinal product be considered not safe, if it has
been used for a long time in folk medicine? This is one
question frequently posed by those who do not consider
legislative rules necessary for the use of herbal medicines.
Safety of herbal medicines is guaranteed in some cases
by long-standing use, but it is not always this case.
Modern phytotherapy includes sometimes the intake of
new plants or new uses of old plants. A lesson for
pharmacologists and physicians on safety aspects of
supposed known plants is deriving from the recent
history of Hypericum perforatum.
A Lesson from Hypericum perforatum
Interest of the scientific community in this plant changed
the approach to medicinal plants and it is possible to
compare this interest with the birth of modern phyto-
therapy and the progressive shift from folk medicine in
the western world. Publication of meta-analysis of Linde
et al. (7) in 1996 marked this important step. Work of
Linde et al. (7) entitled ‘St John’s wort for depression-an
overview and meta-analysis of randomised clinical trials’
examined clinical works published on the effects of
Hypericum perforatum on mild-to-moderate depression.
We think that it is not a pure casuality if the number of
scientific works reporting experiments or clinical studies
on phytotherapy is progressively and rapidly increased
from this point (Fig. 1). Even though Fig. 1 is not the
fruit of a fully scientific methodology, it is surprising to
observe, simply typing the word ‘phytotherapy’ in one of
the most used scientific data banks in the world, the
growing use of this term by scientists.
The authors of this meta-analysis reported two
innovative conclusions: (i) the efficacy of extracts of the
flowers of the plant Hyperium perforatum, standardized
to hypericin (considered for many years the only active
chemical responsible for the effects) at the daily dosage
of 300mg subdivided in three times, was similar to
that of tricyclic anti-depressants and (ii) side effects of
Hypericum perforatum were not relevant and any way
better tolerated than those of tricyclic anti-depressants.
We know that the first part of these conclusions have
been largely confirmed. On the contrary the conclusions
related to safety have been necessarily revised.
What is the reason? What has happened? The facts
linked to the revision of safety of Hypericum perforatum
are easily explainable comparing recent history of the
plant to those of synthetic drugs when they are recently
released in the market. It is well known that a reduced
number of persons have experienced the effects of new
drugs before their commercialization. This underexposi-
tion produces limits in the knowledge of aspects
regarding safety. Some kinds of adverse reactions require
a number of patients larger than included inside the
clinical research occurring before commercialization
(generally about 2000–3000 for drugs). Entry in the
market creates a new situation in which a larger number
of people can potentially intake the new drug. In this new
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Figure 1. Number of scientific articles listed each year on the data
banks Pubmed reporting the word ‘Phytotherapy’ in the period
1990–2004.
42 Herbal medicines: can we do without pharmacologist?condition the possibility exists that adverse reactions
not appeared during clinical trials can be observed.
In other words the ratio risk/benefit of a drug still
not frequently used is automatically not well defined.
This aspect becomes clearer every day and with every
patient. This is well known and leads to monitoring with
particular attention to recently marketed drugs through
pharmacovigilance programs in every country.
The same happened with Hypericum perforatum.
Differently used in folk medicine and whatever poorly
used as antidepressant, rapidly this plant has been used
largely by many people for depressive symptoms. Use of
effective dosage, without contraindications, without
medical supervision and generally for self-medication,
revealed what are the real problems related to its safety.
Today we have learnt to use Hypericum and we do not
give it to patients taking other antidepressants (in
particular serotoninergic drugs) or certain drugs because
of the possible interactions of Hypericum with them. For
its effects on metabolism of other substances, commer-
cialization of Hypericum perforatum in Europe requires a
registration like that of synthetic drugs (8).
The story of Hypericum perforatum has been observed
also for other medicinal herbs. Contraindications for
plants, often represented by interactions with drugs,
are now known also for other plants such as Ginkgo
biloba, Allium sativum and Panax ginseng (9). It is fitting
to remember that medicinal plants still sell as dietary
supplements in most countries. This state of things
worsens the safety use of herbal medicines and it will
be this way until new rules are in effect. Moreover, the
need to better understand the potential toxicity of some
toxic compounds contained in some popular plants
(such as estragole in fennel and anise) and the medicinal
plants that could be used (and at what dosage) in children
and/or adolescents is emerging (10). In conclusion,
antagonistic behavior of pharmacologists versus herbal
medicines is not useful. On the contrary, modern
phytotherapy needs the contribution of researchers with-
out preconceptions trained to evaluate efficacy and safety
of medicinals.
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